111 related articles for article (PubMed ID: 38663957)
1. Targeting KRAS and SHP2 signaling pathways for immunomodulation and improving treatment outcomes in solid tumors.
Sahu P; Mitra A; Ganguly A
Int Rev Cell Mol Biol; 2024; 386():167-222. PubMed ID: 38782499
[TBL] [Abstract][Full Text] [Related]
2. KRAS: Biology, Inhibition, and Mechanisms of Inhibitor Resistance.
Ash LJ; Busia-Bourdain O; Okpattah D; Kamel A; Liberchuk A; Wolfe AL
Curr Oncol; 2024 Apr; 31(4):2024-2046. PubMed ID: 38668053
[TBL] [Abstract][Full Text] [Related]
3. Importance of targeting various cell signaling pathways in solid cancers.
Ghosh C; Hu J
Int Rev Cell Mol Biol; 2024; 385():101-155. PubMed ID: 38663958
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of KRAS inhibitor-directed therapies for pancreatic cancer treatment.
Long SA; Amparo AM; Goodhart G; Ahmad SA; Waters AM
Front Oncol; 2024; 14():1402128. PubMed ID: 38800401
[TBL] [Abstract][Full Text] [Related]
5. Current Landscape of Cancer Immunotherapy: Harnessing the Immune Arsenal to Overcome Immune Evasion.
Mitra A; Kumar A; Amdare NP; Pathak R
Biology (Basel); 2024 Apr; 13(5):. PubMed ID: 38785789
[TBL] [Abstract][Full Text] [Related]
6. Targeting KRAS mutant cancers: from druggable therapy to drug resistance.
Zhu C; Guan X; Zhang X; Luan X; Song Z; Cheng X; Zhang W; Qin JJ
Mol Cancer; 2022 Aug; 21(1):159. PubMed ID: 35922812
[TBL] [Abstract][Full Text] [Related]
7. KRAS mutation: from undruggable to druggable in cancer.
Huang L; Guo Z; Wang F; Fu L
Signal Transduct Target Ther; 2021 Nov; 6(1):386. PubMed ID: 34776511
[TBL] [Abstract][Full Text] [Related]
8. From bench to bedside: current development and emerging trend of KRAS-targeted therapy.
Chen Y; Liu QP; Xie H; Ding J
Acta Pharmacol Sin; 2024 Apr; 45(4):686-703. PubMed ID: 38049578
[TBL] [Abstract][Full Text] [Related]
9. Targeting mutated GTPase KRAS in tumor therapies.
Fan G; Lou L; Song Z; Zhang X; Xiong XF
Eur J Med Chem; 2021 Dec; 226():113816. PubMed ID: 34520956
[TBL] [Abstract][Full Text] [Related]
10. Drugging the undruggable: Advances in targeting KRAS signaling in solid tumors.
Tripathi P; Kumari R; Pathak R
Int Rev Cell Mol Biol; 2024; 385():1-39. PubMed ID: 38663957
[TBL] [Abstract][Full Text] [Related]
11. KRAS: A Promising Therapeutic Target for Cancer Treatment.
Wu HZ; Xiao JQ; Xiao SS; Cheng Y
Curr Top Med Chem; 2019; 19(23):2081-2097. PubMed ID: 31486755
[TBL] [Abstract][Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
